Area of research
Renewable Energy, Sustainability and the Environment · Complementary and alternative medicine
Research interest
Research interests include Cancer research, Medicine, Autophagy, Capecitabine, Epirubicin, and Docetaxel.
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
Caveolin-1 inhibits breast cancer stem cells via c-Myc-mediated metabolic reprogramming
Inhibitory effects of everolimus in combination with paclitaxel on adriamycin-resistant breast cancer cell line MDA-MB-231
Abstract GS1-08: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (cbcsg010): An open-label, randomised, multicentre, phase 3 trial
Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway
Astragaloside IV enhances taxol chemosensitivity of breast cancer via caveolin‐1‐targeting oxidant damage
Broadleaf Mahonia attenuates granulomatous lobular mastitis‑associated inflammation by inhibiting CCL‑5 expression in macrophages
Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
The inflammasome: an emerging therapeutic oncotarget for cancer prevention
Cbcsg-10: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer.
Caveolin-1, a stress-related oncotarget, in drug resistance
MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin
Caveolin-1 mediates chemoresistance in breast cancer stem cells via β-catenin/ABCG2 signaling pathway